Literature DB >> 15146340

Non-neuroleptic approaches to treating negative symptoms in schizophrenia.

Hans-Jürgen Möller1.   

Abstract

The novel/atypical neuroleptics have proven to be effective in treating negative symptoms but although clinical experience appears to show that they have advantages over the traditional neuroleptics in treating negative symptoms, superiority has not always been statistically confirmed and the treatment results in individual patients in everyday clinical practice are often not satisfying. Therefore other drug treatment options also have to be carefully considered. This paper presents a systematic review of non-neuroleptic drug treatments for negative symptoms in schizophrenia, based on MEDLINE searches in the databases from 1995 to September 2002 to identify pertinent clinical trials. Relevant literature was also found in the reference lists of papers identified by the MEDLINE searches. Most of the alternatives to neuroleptics have only been investigated as add-on therapies and not as monotherapies. The SSRIs seem to have a certain place in the treatment of negative symptoms. Anticonvulsants, oestrogens and glutamatergic drugs can currently only be seen as experimental drugs and require further empirical evaluation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146340     DOI: 10.1007/s00406-004-0503-4

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  4 in total

Review 1.  Pharmacological treatment of negative symptoms in schizophrenia.

Authors:  Hans-Jürgen Möller; Pal Czobor
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-04-21       Impact factor: 5.270

2.  Psychotropic effects of antiepileptic drugs.

Authors:  Siddhartha Nadkarni; Orrin Devinsky
Journal:  Epilepsy Curr       Date:  2005 Sep-Oct       Impact factor: 7.500

3.  Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.

Authors:  Shahin Akhondzadeh; Raofeh Ghayyoumi; Farzin Rezaei; Bahman Salehi; Amir-Hossein Modabbernia; Azad Maroufi; Gholam-Reza Esfandiari; Mehrangiz Naderi; Fariba Ghebleh; Mina Tabrizi; Shams-Ali Rezazadeh
Journal:  Psychopharmacology (Berl)       Date:  2010-10-15       Impact factor: 4.530

4.  Concomitant medication of psychoses in a lifetime perspective.

Authors:  Maria Vares; Peter Saetre; Pontus Strålin; Sten Levander; Eva Lindström; Erik G Jönsson
Journal:  Hum Psychopharmacol       Date:  2011-06-22       Impact factor: 1.672

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.